GOSS vs. RCUS, VIR, PAHC, MLYS, SYRE, NRIX, ZYME, AVXL, DAWN, and GYRE
Should you be buying Gossamer Bio stock or one of its competitors? The main competitors of Gossamer Bio include Arcus Biosciences (RCUS), Vir Biotechnology (VIR), Phibro Animal Health (PAHC), Mineralys Therapeutics (MLYS), Spyre Therapeutics (SYRE), Nurix Therapeutics (NRIX), Zymeworks (ZYME), Anavex Life Sciences (AVXL), Day One Biopharmaceuticals (DAWN), and Gyre Therapeutics (GYRE). These companies are all part of the "pharmaceutical products" industry.
Gossamer Bio vs.
Gossamer Bio (NASDAQ:GOSS) and Arcus Biosciences (NYSE:RCUS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, valuation, community ranking, profitability, media sentiment and institutional ownership.
Gossamer Bio currently has a consensus price target of $7.75, suggesting a potential upside of 853.38%. Arcus Biosciences has a consensus price target of $30.25, suggesting a potential upside of 294.39%. Given Gossamer Bio's higher possible upside, analysts plainly believe Gossamer Bio is more favorable than Arcus Biosciences.
Gossamer Bio has higher earnings, but lower revenue than Arcus Biosciences. Gossamer Bio is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks.
In the previous week, Arcus Biosciences had 6 more articles in the media than Gossamer Bio. MarketBeat recorded 9 mentions for Arcus Biosciences and 3 mentions for Gossamer Bio. Arcus Biosciences' average media sentiment score of 0.80 beat Gossamer Bio's score of 0.30 indicating that Arcus Biosciences is being referred to more favorably in the news media.
Gossamer Bio has a net margin of 0.00% compared to Arcus Biosciences' net margin of -102.66%. Arcus Biosciences' return on equity of -45.59% beat Gossamer Bio's return on equity.
Arcus Biosciences received 42 more outperform votes than Gossamer Bio when rated by MarketBeat users. However, 66.67% of users gave Gossamer Bio an outperform vote while only 65.33% of users gave Arcus Biosciences an outperform vote.
Gossamer Bio has a beta of 1.88, meaning that its stock price is 88% more volatile than the S&P 500. Comparatively, Arcus Biosciences has a beta of 1.54, meaning that its stock price is 54% more volatile than the S&P 500.
81.2% of Gossamer Bio shares are owned by institutional investors. Comparatively, 92.9% of Arcus Biosciences shares are owned by institutional investors. 5.0% of Gossamer Bio shares are owned by company insiders. Comparatively, 12.3% of Arcus Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Summary
Arcus Biosciences beats Gossamer Bio on 11 of the 18 factors compared between the two stocks.
Get Gossamer Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for GOSS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Gossamer Bio Competitors List
Related Companies and Tools
This page (NASDAQ:GOSS) was last updated on 4/15/2025 by MarketBeat.com Staff
Buy GOSS Stock Free GOSS Stock Alerts